Descripción de la empresa
Pharvaris N.V. operates as a late-stage biopharmaceutical entity dedicated to the development and commercialization of novel therapies designed to address rare diseases characterized by unmet medical needs, specifically within the domains of angioedema and other bradykinin-mediated conditions. The company's core innovation pipeline centers on deucrictibant, a small molecule formulated as a bradykinin B2-receptor antagonist, which targets specific physiological pathways to manage these rare disorders. This enterprise functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning it among firms that leverage deep scientific expertise to transform biological discoveries into marketable treatments for niche patient populations. With a total market capitalization of $1.78B and an employee base of 118 individuals, the company represents a significant asset in the biotech landscape despite reporting no annual revenue figures in its trailing twelve-month period. The absence of reported revenue combined with a substantial market cap indicates that the company's valuation is primarily derived from its pipeline potential and future commercial prospects rather than current operational earnings, reflecting the typical capital-intensive nature of late-stage biotechnology firms that are investing heavily in R&D before reaching significant commercialization milestones.
Salud financiera
The financial performance metrics for Pharvaris N.V. reveal a company in a heavy investment phase, reporting a net income of $-163,719,488 and an EBITDA of $-167,259,872 over the trailing twelve months, with revenue figures listed as N/A for the same period. The substantial gap between the reported net income and the EBITDA figure highlights a cost structure heavily influenced by significant non-operating expenses or interest costs, as the difference between these two profitability measures is approximately $3.5 million. The company generates a free cash flow of $-76,153,248, indicating that while the business model is not yet cash-flow positive, the entity maintains sufficient liquidity to fund its operations and development activities without immediate dilution of shareholders. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a status common for biotechnology companies that have not yet achieved substantial commercial sales volumes to realize their gross profit potential. On the balance sheet, Pharvaris holds $329.29M in cash against total debt of $578,657, resulting in a debt-to-equity ratio of 0.18, which suggests a highly conservative capital structure with minimal leverage relative to its equity base. The current ratio stands at 12.86, signaling an extremely robust short-term liquidity position that provides ample coverage for current liabilities and operational cash burn. Return on Equity and Return on Assets are recorded at -53.8% and -32.1% respectively, metrics that reflect the aggressive reinvestment strategy typical of pre-revenue biotechs where management is utilizing equity to fund growth rather than generating immediate returns for shareholders.
Evaluación de valoración
Valuation multiples for Pharvaris N.V. present a complex picture typical of high-growth, unprofitable biotechnology stocks, with a trailing P/E ratio listed as N/A due to the absence of positive earnings and a forward P/E of -8.59, which implies expectations of continued negative earnings in the near term. The price-to-book ratio is 4.93, indicating that the market values the company at nearly five times its book value, a premium that investors place on the intangible assets and intellectual property inherent in the biotechnology sector rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -8.66, further underscore that traditional valuation methods based on current profitability or sales are not applicable, necessitating a reliance on pipeline valuation models. The stock's trading range over the past year spans from a low of $11.51 to a high of $29.80, meaning the current share price sits at a level that reflects significant volatility relative to this established price band. The beta coefficient is -2.71, a unique and extreme statistic that suggests the stock's price movements have historically moved inversely to the broader market with high intensity, indicating substantial idiosyncratic risk and non-standard correlation behavior.
Growth & Income
Growth metrics for Pharvaris N.V. show revenue growth and earnings growth listed as N/A, reflecting the reality that the company is currently focused on product development and commercialization rather than scaling revenue streams or expanding earnings in the traditional sense. Consequently, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is retained within the business to finance research and development efforts rather than being distributed to shareholders. This reinvestment approach is standard for late-stage biopharmaceutical companies, where the strategic priority is to advance clinical trials and secure regulatory approvals to unlock future value creation. The overall growth and income profile is defined by a reliance on external capital and internal cash reserves to fund operations, with no current income generation for investors and growth potential entirely dependent on the successful commercialization of its bradykinin B2-receptor antagonist pipeline.